checkAd

     337  0 Kommentare InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants - Seite 2

    Contacts:

    InflaRx N.V.

    Jordan Zwick – Chief Strategy Officer
    Email: IR@inflarx.de
    Tel: +1 917-338-6523

    MC Services AG

    Katja Arnold, Laurie Doyle, Andreas Jungfer
    Email: inflarx@mc-services.eu
    Europe: +49 89-210 2280
    U.S.: +1-339-832-0752

    Lesen Sie auch

    FORWARD-LOOKING STATEMENTS
    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants - Seite 2 JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its …